NCT05494411Available不适用
Named Patient Program for Mitomycin for Pyelocalyceal Solution
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are suitable to receive JELMYTO and for whom there is reasonable expectation that JELMYTO may provide clinical benefit based on the medical judgment of their prescribing physician.
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Managed Access Program for Momelotinib in MyelofibrosisPrimary MyelofibrosisMyelofibrosisNCT05582083GlaxoSmithKline
Approved For Marketing
不适用
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerMetastatic Breast CancerNCT03763604Eli Lilly and Company
No Longer Available
不适用
Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A InfectionH7N9 Subtype of Influenza A VirusNCT03834376Janssen Research & Development, LLC
已完成
2 期
Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or GefitinibNon-small Cell Lung CancerNCT02747953Samsung Medical Center50
No Longer Available
不适用
Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell CarcinomaNCT03492489Regeneron Pharmaceuticals